

Research article

Open Access

## Cooperation between MEF2 and PPAR $\gamma$ in human intestinal $\beta$ , $\beta$ -carotene 15,15'-monooxygenase gene expression

Xiaoming Gong<sup>1,4</sup>, Shu-Whei Tsai<sup>1</sup>, Bingfang Yan<sup>3</sup> and Lewis P Rubin<sup>\*1,2,4</sup>

Address: <sup>1</sup>Department of Pediatrics, Women and Infants' Hospital of Rhode Island and Brown Medical School, Providence, Rhode Island, USA, <sup>2</sup>Program in Fetal Medicine, Women and Infants' Hospital of Rhode Island and Brown Medical School, Providence, Rhode Island, USA, <sup>3</sup>Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island, USA and <sup>4</sup>Department of Cell Biology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

Email: Xiaoming Gong - gongx@ccf.org; Shu-Whei Tsai - Shu-Whei\_Tsai@brown.edu; Bingfang Yan - bya8505u@postoffice.uri.edu; Lewis P Rubin\* - rubinl@ccf.org

\* Corresponding author

Published: 21 February 2006

Received: 19 August 2005

*BMC Molecular Biology* 2006, **7**:7 doi:10.1186/1471-2199-7-7

Accepted: 21 February 2006

This article is available from: <http://www.biomedcentral.com/1471-2199/7/7>

© 2006 Gong et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Vitamin A and its derivatives, the retinoids, are essential for normal embryonic development and maintenance of cell differentiation.  $\beta$ ,  $\beta$ -carotene 15,15'-monooxygenase I (BCMOI) catalyzes the central cleavage of  $\beta$ -carotene to all-*trans* retinal and is the key enzyme in the intestinal metabolism of carotenes to vitamin A. However, human and various rodent species show markedly different efficiencies in intestinal BCMOI-mediated carotene to retinoid conversion. The aim of this study is to identify potentially human-specific regulatory control mechanisms of BCMOI gene expression.

**Results:** We identified and functionally characterized the human BCMOI promoter sequence and determined the transcriptional regulation of the BCMOI gene in a BCMOI expressing human intestinal cell line, TC-7. Several functional transcription factor-binding sites were identified in the human promoter that are absent in the mouse BCMOI promoter. We demonstrate that the proximal promoter sequence, nt -190 to +35, confers basal transcriptional activity of the human BCMOI gene. Site-directed mutagenesis of the myocyte enhancer factor 2 (MEF2) and peroxisome proliferator-activated receptor (PPAR) binding elements resulted in decreased basal promoter activity. Mutation of both promoter elements abrogated the expression of intestinal cell BCMOI. Electrophoretic mobility shift and supershift assays and transcription factor co-expression in TC-7 cells showed MEF2C and PPAR $\gamma$  bind to their respective DNA elements and synergistically transactivate BCMOI expression.

**Conclusion:** We demonstrate that human intestinal cell BCMOI expression is dependent on the functional cooperation between PPAR $\gamma$  and MEF2 isoforms. The findings suggest that the interaction between MEF2 and PPAR factors may provide a molecular basis for interspecies differences in the transcriptional regulation of the BCMOI gene.

### Background

Vitamin A, an essential micronutrient, is required for

embryonic development and pattern formation, postnatal growth, reproduction, epithelial maintenance, immunity

and vision [1-5]. With the exception of the retina, where 11-*cis*-retinal acts as the chromophore for rhodopsin [6], biological activities of vitamin A are largely mediated by isomers of retinoic acid (RA). RAs bind members of the RA receptor (RAR) and retinoid X receptor (RXR) families of ligand-dependent transcription factors to regulate transcriptional rates of retinoid response genes. Vitamin A deficiency is associated with histological abnormalities in epithelial tissues [7], decreased host resistance to tumor cells and infectious organisms [8], and increased susceptibility to environmental carcinogens [9].

Animals, incapable of synthesizing vitamin A *de novo* from isoprenoid precursors, require dietary intake of preformed vitamin A, largely as retinyl esters, or must derive retinoids from metabolism of plant  $\beta$ -carotene and related carotenoids. In humans, provitamin A carotenoids contribute 40–80% of total vitamin A stores [10]. Conversion of  $\beta$ -carotene to vitamin A is catalyzed by the enzyme  $\beta$ ,  $\beta$ -carotene 15,15'-monooxygenase (E.C. 1.13.11.21., BCMO1) [11,12]. The structurally related  $\beta$ -carotene 9',10'-oxygenase (BCMO2) catalyzes the quantitatively minor eccentric cleavage of  $\beta$ -carotene to  $\beta$ -apo-10'-carotenal, retinol and  $\beta$ -ionone [13,14].

In rodents, nearly all absorbed  $\beta$ -carotene is converted to retinol in the intestine [15] except at very high doses [16]. In contrast, humans convert only a portion of ingested  $\beta$ -carotene to vitamin A so that up to 15–30% of absorbed  $\beta$ -carotene remains intact [17-19] and is delivered to tissues. Several lines of evidence suggest that intestinal BCMO1 activity is subject to transcriptional regulation [20,21]. However, the mechanisms governing species-specific differences in efficiency of dietary  $\beta$ -carotene to retinoid cleavage remain unclear.

The human BCMO1 cDNA encodes a 63-kDa protein with homologies to members of a large and diverse family of polyene chain oxidases and carotenoid cleavage enzymes [22,23]. Although BCMO1 can be detected in several tissues, its expression is most pronounced in intestinal mucosa and liver [24]. BCMO1 expression is downregulated in rat intestine by  $\beta$ -carotene and RA [20]. In addition, recent data demonstrated that peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) regulates transcription of the mouse BCMO1 gene [21]. The human BCMO1 promoter sequences required for regulation of BCMO1 gene expression have not previously been defined.

We have isolated and characterized the human BCMO1 promoter region and identified several functional *cis*-acting elements. We report that in the human, unlike murids, myocyte enhancer factor 2 (MEF2) and PPAR transcription factors interactively regulate intestinal cell BCMO1

gene expression. These data suggest that cooperation between MEF2 and PPAR factors may provide a molecular basis for the species differences between rodent and human in the transcriptional regulation of BCMO1 gene.

## Results

### Identification of *cis*-acting elements in the BCMO1 promoter


Computational analysis of putative *cis*-acting elements located within the  $\sim$ 1.0 kb human BCMO1 5'-flanking sequence was performed using the TRANSFAC database [25] and TESS program. Several potential *cis*-acting elements were identified including, but not limited to, putative binding sites for CRE, RAR, MEF2, C/EBP, IRF1, GATA1, AP2 and PPAR, and a TATA box (Additional File 1, A). Since the mouse BCMO1 gene is regulated by PPAR $\gamma$  [21], initially we examined functionality of the PPAR binding sequence in the human promoter. Comparison between the human and mouse BCMO1  $\sim$ 1.0 kb of genomic 5'-flanking sequences revealed approximately 33% homology with considerable gaps (Additional file 1, B). Several potential protein-DNA binding sites including those for IRF1, GATA1, AP2, PPAR and TATA are present in the same sequential order in the human and mouse BCMO1 promoters.

### Functional analysis of human BCMO1 basal promoter activity in TC-7 cells


To evaluate the functionality of these potential *cis*-acting elements, the  $\sim$ 1.0 kb nucleotide sequence upstream from the human BCMO1 coding sequence start site was excised from pBCO1022-CR (Additional File 1, A) and ligated into the pGL3-basic luciferase reporter vector (pGL3-BCO1022). To determine whether this sequence confers promoter activity, several cell lines including TC-7 were transiently transfected with the pGL3-BCO1022 reporter (data not shown). The human intestinal CaCo-2 derived TC-7 cell line is unusual in that it has significant endogenous BCMO1 activity [26]. We also have determined by RT-PCR that the parent CaCo-2 cell line expressed BCMO1 mRNA, although at very low levels (data not shown). Figure 1A shows this cloned DNA fragment drives enhanced luciferase expression in TC-7 cells.

To map the region in the BCMO1 gene that influences expression of the luciferase reporter construct, the  $\sim$ 1.0 kb promoter sequence was progressively deleted from the 5'-end by nested PCR to generate the deletion clones pGL3-BCO682, pGL3-BCO328, pGL3-BCO218, pGL3-BCO147 and pGL3-BCO59. Each construct was transfected into TC-7 cells. The expression vector pCMV- $\beta$ -Gal was used as an internal control for adjusting transfection efficiency. As shown in Fig. 1B, deletion of the 5'-flanking 340 bp (-647/+35 promoter fragment) minimally changed luciferase activity compared to the full-length, -987/+35 genomic

**A**



**B**



**Figure 1**

**Mapping of the regulatory elements in the BCMO1 promoter in TC-7 cells.** **A.** Transactivating activity of human BCMO1 promoter. A 1022-bp fragment was used for the construction of the BCMO1 reporter plasmid, pGL3-BCO1022, as described in "Methods". Luciferase activity was measured in total cell extracts obtained from TC-7 cells 24 h after transient transfection and compared with cellular luciferase activity for transfection of the control empty vector, pGL3-basic. **B.** Above, a schematic diagram of the BCMO1 promoter reporter construct (pGL3-BCO1022) showing the location of putative transcription factor binding sites. Below, deletion analysis of the BCMO1 -987/+35 promoter fragment. TC-7 cells were transiently transfected with luciferase reporter constructs containing serial deletions of BCMO1 5'-flanking DNA. Cells were transfected with reporter constructs (0.3 μg/well) and a β-Gal expression vector was added as an internal control. After 24 h, cells were lysed and luciferase and β-Gal activities were measured. Results are means ± S.D. of three or more independent experiments each performed in triplicate. \*,  $p < 0.05$ , \*\*,  $p < 0.001$ .

fragment. Further deletions of the 5'-flanking sequence (-293/+35 and -197/+35) progressively decreased luciferase activity by 25-30%. Deletion of an additional 5'-flanking 85 bp (-112/+35 promoter sequence) that includes putative MEF2, C/EBP and IRF1 sites, dramatically decreased reporter gene expression. Further deletion completely abolished BCMO1 reporter activity. As a negative control, TC-7 cells transfected with empty vector (pGL3-basic) showed no significant luciferase activity. Transfection of the minimal promoter fragment (pGL3-BCO147) containing the PPAR site (-55/-43) resulted in an approximate 12-fold induction of luciferase activity compared with the pGL3-basic vector (Figure 1B).

#### **MEF2 and PPAR sites in the BCMO1 promoter and basal transcription**

The ~200 bp genomic DNA region proximal to the transcriptional start site was further investigated to determine which specific *cis*-acting elements confer basal expression of the human BCMO1 gene. Sequence analysis suggested the presence of a MEF2 binding site (TGCTTATTTAGA) (Additional file 1, A) that is absent in the mouse promoter, and a PPAR/RXR binding site (TAACCTTTAACCA) conserved in the mouse promoter. Therefore, the MEF2 site was mutated (Figure 2A) to test its contribution to basal transcriptional activity. As shown in Figure 2B, transfection of a reporter construct containing the mutated MEF2 binding site resulted in an approximately 30% reduction in luciferase activity compared to the wild type construct, pGL3-BCO218. A much greater reduction in reporter gene activities (pGL3-BCO218 and pGL3-BCO147) resulted from mutation of the PPAR site lying within the proximal promoter sequence. Mutation of both MEF2 and PPAR sites within the proximal promoter region of BCMO1 (pGL3-BCO218) abrogated the expression of reporter gene.

#### **Verification of MEF2 and PPAR binding to the BCMO1 promoter**

The following experiments were undertaken to verify that endogenous transcription factors bind to these different BCMO1 proximal promoter response elements. As shown in the Western blots reproduced in Additional file 2A, TC-7 cell nuclear extracts contain PPAR isoforms (PPAR $\alpha$ ,  $\beta$  and  $\gamma$ ), RXR $\alpha$ , RAR $\beta$  and MEF2 isoforms (MEF2A, 2C and 2D). The capacity of MEF2 to bind the corresponding BCMO1 elements was then tested using EMSA with TC-7 nuclear protein extracts and radiolabeled probes corresponding to the wild type or mutated MEF2 binding sequence (nt -188 to -165) (additional file 2B). A MEF2 DNA-protein complex was detected (Additional File 2C, left panel) having electrophoretic mobilities corresponding to heterodimeric or homodimeric MEF2 isoforms, consistent with previously reported observations [27]. Specificity of MEF2 binding was verified by three criteria.

First, specific DNA-protein binding was eliminated by the addition of 100-fold molar excess of the non-radiolabeled specific oligonucleotide. Second, substitution of radiolabeled oligonucleotide in which the MEF2 site was mutated also abolished DNA-protein complex formation (Additional File 2C, left panel). Finally, to further assess the identity of TC-7 cell nuclear proteins binding to the MEF2 site, supershift analysis was performed using specific MEF2 antibodies. The radiolabeled probe corresponding to the MEF2 binding site was supershifted by addition of an antibody to MEF2C to an extent that corresponded to its abundance in TC-7 cell nuclei (Additional file 2A). Supershift assays showed diminished intensity of DNA-protein complex with antibody against MEF2A and an appearance of a supershifted band with antibody against MEF2D. (Additional file 2C, right panel).

Interrogation of the BCMO1 promoter PPAR-response element (PPRE) (-60/-37) using EMSA yielded a single PPRE DNA-protein band with the expected mobility (additional file 2D, left panel). Similar to the MEF2 EMSA, this binding was specific, as it was inhibited by addition of excess cold specific oligonucleotide and abolished by substitution of a mutated PPRE oligonucleotide probe (additional file 2B and 2D, left panel). The specificity of this interaction was further observed by the supershift assay. Binding of members of the PPAR family of transcription factors, RXR and RAR transcription factors was demonstrated using the PPAR site (-60/-37) as a probe. The results showed diminished intensity of the bound lower band (relative to the upper band) with addition of antibodies against PPAR $\gamma$  and RXR $\alpha$  as well as the appearance of a weakly detectable supershifted band with addition of RXR $\alpha$  antibody (Additional file 2D, right panel). The extent of supershift with PPAR $\gamma$  antibody corresponded to its low abundance in TC-7 cell nuclei as shown in Additional File 2A.

The region of the human BCMO1 promoter flanked by the MEF2 (-185/-173) and AP2 (-69/-61) elements contains a cluster of potential regulatory elements. A comparison of this DNA region to the BCMO1 5'-flanking regions in other currently sequenced genomes shows the MEF2 site (-185/-173) and a putative C/EBP site (-165/-155) are uniquely present in the human BCMO1 promoter (data not shown). The C/EBP DNA response element showed specific transcription factor binding in TC-7 cells, but DNA-protein binding did not significantly alter transcriptional activity of the promoter reporter constructs (data not shown). Putative IRF-1 and GATA1 binding sites in this region are represented both in the aligned human and mouse BCMO1 promoters. However, no specific protein binding to either of these DNA elements in the TC-7 cell system was detected (data not shown).

**A**

**Wild-type MEF2 site** 5' - TCTGCTT**ATT**TAGAACCTAGTCTG - 3'

**Mutated MEF2 site** 5' - TCTGCTT**C**TTT**A**CAACCTAGTCTG - 3'

**Consensus MEF2 (Reverse)** TTTATTTAG


  

**Wild-type PPAR site** 5' - GGAAATTAACCTTT**AA**CCAAACAT - 3'

**Mutated PPAR site** 5' - GGAAATTAAC**G**CTT**A**CCAAACAT - 3'

**Consensus PPAR (Reverse)** TGACCTGTGACCT

**B**



**Figure 2**

**Functional analysis of the BCMO1 promoter mutated regulatory sequences. A.** Comparison of wild type and mutant sequences for the BCMO1 promoter MEF2 binding site (-187/-163) and PPAR binding site (-61/-37). Mutated base pairs are underlined and *in bold*. **B.** Site-directed mutations (*in solid black*) were introduced into the binding sites of both MEF2 and PPAR transcription factors. TC-7 cells were transfected with 0.3 µg/well of luciferase reporter constructs containing BCMO1 proximal promoter fragments of 218 bp or 147 bp in length or with the corresponding mutated sequences. Data are expressed as a relative fold luciferase activity compared to that of the empty vector. Results shown are means ± S.D. of three or more independent experiments each performed in triplicate. \*, *p* < 0.05, \*\*, *p* < 0.001.

**Cooperation of MEF2C and PPAR $\gamma$ /RXR $\alpha$  in intestinal BCMO1 promoter activity**

As an alternative strategy for characterizing the dependence of BCMO1 transcription on MEF2 and PPAR isoforms, in various experiments we co-transfected a

proximal BCMO1 reporter construct (pGL3-BCO218) with mammalian expression vectors for MEF2C, PPAR $\gamma$ , RXR $\alpha$  or PPAR $\gamma$ /RXR $\alpha$ , each of the latter under the control of a cytomegalovirus or Rous sarcoma virus promoter. Relative luciferase activity was normalized to that result-

ing from co-transfection with the empty vector, pcDNA3. Cells in which MEF2C was over-expressed showed an approximately three-fold increase in relative luciferase activity. Conversely, expression of a dominant negative MEF2 (MEF2A-131) reduced activity of the BCMO1 promoter reporter gene by half (Additional File 3A). As shown in Additional File 3B, approximately 1.5, 1.4 and three-fold increases in pGL3-BCO218 luciferase activity were induced by PPAR $\gamma$ , RXR $\alpha$  and PPAR $\gamma$ /RXR $\alpha$ , respectively. Surprisingly, co-expression of MEF2C plus PPAR $\gamma$ /RXR $\alpha$  resulted in a six-fold stimulation of the BCMO1 reporter expression (Additional File 3B), indicating MEF2 and PPAR $\gamma$  have an additive effect on BCMO1 promoter activity.

The role of the PPRE in the BCMO1 promoter sequence was further probed using co-expression of PPAR $\gamma$ /RXR $\alpha$  with the reporter construct containing the BCMO1 minimal promoter sequence (pGL3-BCO147). This DNA fragment contains the PPRE but lacks the MEF2 sites. The resulting reporter gene activity was dramatically amplified. As a control condition, co-expression of PPAR $\gamma$ /RXR $\alpha$  with this BCMO1 minimal promoter sequence in which the PPRE was specifically mutated resulted in no increase in luciferase activity (Additional File 3C).

To confirm the additive effects of MEF2C and PPAR $\gamma$  in BCMO1 promoter activation, we utilized BCMO1 promoter constructs in which the respective response elements were mutated. Wild type and mutated promoter constructs were then co-transfected into TC-7 cells with MEF2C or PPAR $\gamma$ /RXR $\alpha$  alone or in combination. As shown in Additional File 3D, the wild type proximal promoter (pGL3-BCO218) enhanced BCMO1 reporter activity when co-transfected with MEF2C, PPAR $\gamma$ /RXR $\alpha$  or the combination of MEF2C and PPAR $\gamma$ /RXR $\alpha$ . Mutation of the MEF2 site (pGL3-BCO218-mutMEF2), but not of the PPAR site, significantly reduced this enhanced BCMO1 reporter expression by 24–30%. Conversely, mutation of the PPRE (pGL3-BCO218-mutPPAR) not only dramatically decreased basal BCMO1 promoter activity, but also decreased the MEF2C and PPAR $\gamma$ -induced activation. The combinatorial effects of MEF2C plus PPAR $\gamma$ /RXR $\alpha$  on the BCMO1 reporter gene were abolished when either the MEF2 site or PPAR site were mutated.

## Discussion

Although the *in vivo* enzymatic reaction first was described in 1930 by Moore [28], identification of  $\beta$ -carotene oxygenase activity was only demonstrated in 1965 when Olsen and Hayaishi [11] and Goodman and Huang [12] independently showed rat small intestine homogenates enzymatically cleave  $\beta$ -carotene at the 15,15'-carbon double bond to yield two molecules of vitamin A aldehyde (retinal). More recently, this central cleavage enzyme,

BCMO1, was purified [29,30], mouse [31–33] and human [34] cDNAs were identified and the human recombinant enzyme was biochemically characterized [35] as a monooxygenase [36].

Cleavage of  $\beta$ -carotene has been shown to be a source of target tissue retinoic acid production in the small intestine, liver, kidney, lung and testis [37]. In addition to considerable apparent tissue-specific regulation [[20], unpublished data], BCMO1 is subject to species differences in the efficiency of intestinal  $\beta$ -carotene to retinoid cleavage. The goal of the current studies was to identify the basal promoter and core transcriptional elements responsible for regulating human BCMO1 expression in intestinal cells. The use of CaCo-2 derived TC-7 cells was prompted by their demonstrated endogenous BCMO1 activity. TC-7 cells have a phenotype even closer to small intestine enterocytes than does the parental population gauged by expression of several additional differentiation-associated proteins and nutrient absorption patterns [38,39].

The comparison of the human and mouse promoter sequences by ClustalW and manual inspection revealed little interspecies homology. Whether this finding is relevant to the marked species differences in carotenoid absorption and metabolism is not known. In humans, although the majority of absorbed  $\beta$ -carotene can be converted in the intestine directly to retinal [17,18,40], considerable  $\beta$ -carotene levels are detected in blood. In rodent small intestine, nearly all  $\beta$ -carotene is directly cleaved to retinal, leaving little intact  $\beta$ -carotene in the circulation.

Recent data emphasize the concept that interspecies expression differences, especially in structural genes such as enzymes, are less the result of select *trans*-regulatory changes with widespread effects, but rather of many *cis*-acting changes spread throughout the genome [41,42]. The sequence context of the genomic DNA regions that contain protein-binding sites may determine whether these regions function in transcriptional regulation. Since closely spaced transcription factor binding sites can facilitate protein-protein interactions, clustering of protein-binding elements is often a hallmark of a subset of the control regions in genomic DNA [43–46].

We found the proximal 700 bp of genomic 5'-flanking sequence conferred maximal BCMO1 promoter activity in a homologous human intestinal cell system. Our functional studies (promoter deletion experiments, site-directed mutagenesis assays, EMSA, supershift, ability to drive expression of reporter genes) establish that the minimal region of the human BCMO1 promoter required for induction of the gene is located within 200 bp upstream

from the start site of transcription, a region that contains a cluster of *cis*-acting elements. Mutation of the PPRE or MEF2 binding sites reduced basal promoter activity. Mutation of both promoter elements abrogated BCMO1 transcription in intact cells, a result additive of the effects of mutating either site singly. Coupled with the direct experimental confirmation of specific binding, the PPRE and the human-specific MEF2 site together regulate basal BCMO1 expression. This result differs from the mouse, in which the PPRE solely is both necessary and sufficient for the restricted expression of BCMO1 [21].

The MEF2 family of transcription factors was initially identified from muscle cells due to binding to an A/T rich consensus sequence [c/tTA(A/T<sub>4</sub>)TAg/a] found in the regulatory region of many muscle specific genes [47]. It since has become apparent that MEF2 transcription factors participate in diverse gene regulatory programs, including those for muscle and neural differentiation, cardiac morphogenesis and blood vessel formation [48]. Four mammalian isoforms of MEF2 (A to D), encoded by separate genes, have been identified [47]. However, although MEF2 has been shown to play important roles in several cell types including skeletal muscle, neurons, T cells and other non-muscle cells [48-50], to our knowledge, a role for MEF2 has not previously been described in intestinal epithelial cells. In the present work, we provide evidence that three isoforms of MEF2 (MEF2A, C and D) are expressed in intestinal TC-7 cells (Additional file 2A). Isoforms of MEF2 have been studied in several biological systems, including muscle, neurons, and immune cells, where multiple isoforms are present [48]. Whether different isoforms of MEF2 present in the same cell may perform distinct molecular functions remains largely unknown. Complexity arises from the observations that different isoforms of MEF2 can form either heterodimers or homodimers having apparently indistinguishable DNA-binding specificity. Our data show MEF2C is the major MEF2 isoform that binds to BCMO1 promoter. Consistent with this observation, our data showed that over-expression of MEF2C significantly transactivated BCMO1 reporter gene activity in TC-7 cells.

MEF2 proteins interact with and potentiate the action of other classes of lineage-specific transcription factors. In the present study, we also demonstrated that MEF2C and PPAR $\gamma$  cooperatively regulate BCMO1 gene expression, an observation reminiscent of the interaction between MEF2 proteins and myogenic bHLH factors in skeletal muscles. Several studies have reported functional interaction between MEF2 proteins and members of the nuclear receptor superfamily, such as MEF2A and thyroid hormone receptor (TR) synergism to activate  $\alpha$ -cardiac MHC gene expression [51] and MEF2C and PPAR $\alpha$  cooperation to induce human carnitine palmitoyltransferase 1 $\beta$

(CTB1 $\beta$ ) gene activation [52]. Given the co-expression of MEF2 and PPAR factors in several cell types including intestinal epithelial cells, the PPAR-dependent MEF2 pathway described in this work may provide a molecular paradigm for understanding the mechanism of action of MEF2 in many target cells.

Changes in expression magnitude and relative expression of genes can be a governing mechanism driving species diversification [42] via adaptation to ecological, including nutritional, niches. The importance of BCMO1 gene expression in the maintenance of vitamin A sufficiency makes the BCMO1 promoter a likely target for natural selection. Interspecies differences in efficiency of  $\beta$ -carotene metabolism raise the question whether different regions of the BCMO1 promoter have evolved under heterogeneous dietary constraints. The limitations of the present study preclude associating the human specific regulation of BCMO1 with specific metabolic consequences. Nevertheless, our data suggest physiological hypothesis as only certain DNA sequences functional for the binding of activators are conserved.

Further investigation should advance the understanding of transcriptional control of the key step in  $\beta$ -carotene to vitamin A conversion and, consequently, may have relevance for physiology and human health.

## Conclusion

We showed that the proximal  $\sim$ 200 bp of BCMO1 promoter region is essential for basal promoter activity of human BCMO1 in intestinal TC-7 cells. PPAR $\gamma$  is essential but not sufficient to activate human BCMO1 gene expression. BCMO1 expression is dependent on the cooperation between PPAR $\gamma$  and MEF2 isoforms. An understanding of the transcription factors and *cis*-acting elements involved in regulation of the human BCMO1 expression should facilitate a better understanding of the regulation of BCMO1 expression in physiologic and pathologic states of Vitamin A formation.

## Methods

### Cell line, reagents and plasmids

Clone TC-7 [53] of the human intestinal Ca Co-2 parent cell line was obtained from Dr. Alexandrine During, USDA Human Nutrition Research Center, Beltsville, MD. The PPAR $\gamma$  agonist (GW1929) and antagonist (GW9662), PPAR $\alpha$  agonist (WY14643) and antagonist MK886, and PPAR $\beta$  agonist (GW501516) were obtained from Alexis Biochemicals (San Diego, CA). The PPAR $\alpha$ , PPAR $\beta$  and PPAR $\gamma$  expression vectors were the gifts of Dr. D.P. Kelly (Washington University School of Medicine, St. Louis, Mo.). The RXR $\alpha$ , RAR $\beta$  and  $\beta$ -galactosidase ( $\beta$ -Gal) expression vectors were gifts of Dr. P. Lefebvre (Ligue Nationale Contre le Cancer, Paris, France). The MEF2C

**Table 1: Oligonucleotides used in PCR-based site-directed mutagenesis**

Primer sequence	Mutated site <sup>a</sup>
5'-GGAAATTAACCGCTTAACCAAAC-3'	PPAR/RXR -52/-50
5'-TAGTCIGAAAGTAGCTTTT-3'	C/EBP -161/-159
5'-TCTGCTCTTTTACAACCTAGTCTG-3'	MEF2 -179/-174
5'-ACTCCTGTGCTCAAAGTGTGCCG-3'	CRE/RAR -633/-623

<sup>a</sup>Initiation site for BCMO1 transcription, +1. The mutated nucleotides are in bold.

and MEF2A-131 (dominant negative form of MEF2, DnMEF2) expression vectors were gifts from Dr. Zixu Mao (Brown Medical School, Providence, R.I.).

### Cloning of the 5'-flanking region of the human BCMO1 gene

A 1022 bp BCMO1 promoter fragment spanning nt 79828775 to 79829795 [Ensembl Gene, ENSG00000135697] [54] was amplified by the polymerase chain reaction (PCR) from human liver genomic DNA (BioChain Institute, Hayward, CA) using a 5' primer, 5'-GAATTCAGGCAATGGCAAC-3' (corresponding to genomic DNA sequence nt 79828775 to 79828795) and a 3' primer, 5'-ACTTGTCCCTCTCCAAGAGC-3' (corresponding to nt 79829775 to 79829795). The PCR product was gel purified and ligated into pCR2.1 using a TA Cloning Kit (Invitrogen Corp., Carlsbad, CA) to create pBCO1022-CR. Orientation was confirmed by DNA sequence analysis.

### Construction of luciferase plasmids

The plasmid pGL3-basic (Promega Corp.) was used to construct pGL3-BCO1-Luc plasmids containing BCMO1 promoter fragments. pGL3-BCO1(-987/+35)-Luc, containing the DNA 5'-flanking sequence nt -987 to +35 (relative to the transcription start site [+1]), was excised from pBCO1022-CR by double digestion with *KpnI* and *XhoI*, ligated into the *KpnI/XhoI* sites of pGL3-Basic using T4 DNA ligase and sequenced to verify orientation. This full-length reporter plasmid was designated pGL3-BCO1022. To generate progressive 5'-unidirectional deletion mutants by PCR, a series of forward primers was used in combination with the same reverse primer and pGL3-BCO1022 as template. The reverse primer (with the *XhoI* site underlined) was 5'-CCGCTCCGAGGGTGCCGAGGGAGATC-3'. The forward primers, each of which included the *KpnI* restriction site (underlined), began with: -647 (5'-CGGGGTACCGGTCTCGAACTCCTG); -293 (5'-CGGGG-TACCTAATTCACAGCACCTC); -197 (5'-CGGGGTACCG-GAATTCTCTCTGC); -112 (5'-CGGGGTACCAAAGCTGAGGGC); and -24 (5'-CGGGGTACCGAGCGCAGCTTCCCTTG). The PCR products were gel-purified, digested with *KpnI* and *XhoI*, and subcloned into the *KpnI/XhoI* sites of pGL3-Basic. They

were designated pGL3-BCO682, pGL3-BCO328, pGL3-BCO218, pGL3-BCO147 and pGL3-BCO59, respectively. Each construct was verified by sequencing the insert and plasmid flanking region.

### Site-directed mutagenesis

To generate site-directed mutants of the cAMP response element-binding protein (CREB), RAR, MEF2, CCAAT/enhancer binding protein (C/EBP) and PPAR DNA elements that are located from nt -647 to -56, the Quick-Change site-directed mutagenesis kit (Stratagene, La Jolla, CA) was used according to the manufacturer's instructions. The oligonucleotides used to create the mutations are listed in Table 1, with the mutated nucleotides in bold and underlined throughout (The complementary strand sequences are not shown). Mutation of each binding sequence was confirmed by DNA sequencing.

### Transient transfection and luciferase assays

The TC-7 subline of CaCo-2 cells was cultured in Dulbecco's Modified Eagle's Medium (DMEM, Life Technologies Inc., Gaithersburg, Md.) supplemented with penicillin (100 units/ml), streptomycin (100 µg/ml) (Life Technologies), and 20% fetal bovine serum (HyClone, Logan, Ut.) at 37°C in a humidified atmosphere of 95% air and 5% CO<sub>2</sub>. Cells were plated in 12-well tissue culture dishes at a density of 5 × 10<sup>4</sup> cells/well for 24 h before transfection. At 70–90% confluence, cells were transfected with 0.3 µg of the indicated constructs using 1 µl of LipofectAMINE 2000 transfection reagent per well mixed in Opti-MEM I (Invitrogen). Co-transfection with a β-galactosidase expression plasmid was used to determine efficiency of each transfection. For the co-transfection assays, the total amount of DNA for each transfection was kept constant by using a control vector (pcDNA3). At various time points, cell lysates were analyzed for luciferase and β-galactosidase activities. Luciferase activity relative to the pGL3-basic transfectants was determined after adjustment for β-galactosidase level. All transfections were performed in triplicate for at least three independent experiments.

### Electrophoretic mobility shift assay (EMSA) and supershift assays

Nuclear extracts from TC-7 cells were prepared as described previously [21]. Double-stranded oligonucleotides containing sequences from the human BCMO1 promoter (shown in Table 2) were synthesized (Operon Biotechnologies, Inc., Huntsville, Ala.). EMSA reaction mixtures (20 µl final volumes) included 5–15 µg of nuclear extract, 25 mM HEPES, 100 mM KCl, 0.1% Nonidet P-40 (v/v), 1 mM dithiothreitol, 5% glycerol and 1 µg of poly(dI-dC) (Sigma, St. Louis, Mo.) as a nonspecific competitor. After incubation for 20 min on ice, 20 fmol of [γ-<sup>32</sup>P]-ATP end-labeled probe was added and the reaction was incubated for 30 min at room temperature. Protein-



**Table 2: Oligonucleotides used for EMSA for putative binding sites**

Oligonucleotide sequence <sup>a</sup>	DNA element
5'-GCTTGGAATTAACCTTTAACCAACAT-3'	Wild-type PPAR
5'-GCTTGGAAT <u>I</u> AtgCTTTA <u>t</u> gCAAACAT-3'	Mutated PPAR
5'-GGATTA <u>A</u> AGATTAGCTATGACACCATG-3'	Wild-type GATA-1
5'-GGATTA <u>A</u> ctcTTAGCTATGACACCATG-3'	Mutated GATA-1
5'-GGTTAAGTCAAAAGTGAAACTGGAG-3'	Wild-type IRF-1
5'-GGTTAAGTCA <u>t</u> cAGTGAAACTGGAG-3'	Mutated IRF-1
5'-CTCTCIGCTTATTTAGAACCTAGTC-3'	Wild-type MEF2
5'-CTCTCIGCTT <u>g</u> TTTAcAACCTAGTC-3'	Mutated MEF2
5'-GAACTCCTGACCTCAAGTGACCCGCCAC-3'	Wild-type CRE/RAR
5'-GAACTCCTG <u>t</u> cCTCAAGT <u>g</u> tCCGCCAC-3'	Mutated CRE/RAR

<sup>a</sup> Upper strands of oligonucleotides with putative consensus sequences are *underlined*; the mutated nucleotides are in *lower case characters*.

DNA complexes were separated on a 5% non-denaturing polyacrylamide gel in 0.5 × Tris-borate-EDTA buffer at 25°C. For competition assays, 100-fold molar excess of unlabeled double-stranded oligonucleotide competitor was incubated together with the nuclear extract prior to adding the <sup>32</sup>P-labeled probe. For supershift EMSA, antibodies were preincubated with the nuclear extract mixtures in the binding reaction for 20 min before the probe was added.

#### Western blot analysis

TC-7 cells were harvested, lysed in 1 ml of phosphate-buffered saline (PBS) containing 1% Triton X-100, 0.1% SDS, 1 mM dithiothreitol and 1 mM phenylmethylsulfonyl fluoride and centrifuged at 1,500 × g for 5 min. Protein concentrations were determined by the BCA protein assay (Pierce Biotechnology, Inc., Rockford, IL), and 40 μg cell lysate samples were fractionated by SDS-PAGE. Proteins were transferred to Immobilon-P membranes (Millipore, Billerica, MA) by semi-dry blotting. The membrane was treated according to a standard Western Blotting protocol with chemiluminescence detection. Rabbit polyclonal MEF2C (Cell Signaling Technology, Inc., Beverly, Mass.), MEF2D (BD Transduction Laboratories, Lexington, Ky.), MEF2A, PPARα, PPARβ, PPARγ, RARα and RXRα (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies were diluted to 1:500 to 1:1000 in PBS, 5% non-fat dry milk. Protein-antibody interactions were detected by enhanced chemiluminescence (Amersham Biosciences Corp., Piscataway, NJ).

#### Statistics

Each experiment was performed in triplicate, and the reporter values represent the mean of three to five separate cultures ± standard deviation. The significance of the difference was determined using Student's *t* test.

#### Abbreviations

BCMO1, β, β-carotene 15, 15'-monooxygenase 1; RA, retinoic acid; RAR, retinoic acid receptor; RXR, retinoid X

receptor; C/EBP, CCAAT/enhancer-binding protein; MEF2, myocyte enhancer factor 2; PPAR, peroxisome proliferator-activated receptor; PPRE, PPAR-response element; EMSA, electrophoretic mobility shift assay;

#### Authors' contributions

X.G.: performance and interpretation of all experiments and manuscript preparation; S.T.: participation in the planning of the study; B.Y.: support to X.G.s' experiments; L.P.R.: conceived the study, design and coordination of the study, manuscript preparation. All authors read and approved the final version of the manuscript.

#### Additional material

##### Additional file 1

Identification of human BCMO1 promoter

A. Nucleotide sequence of the human β, β-carotene 15,15'-monooxygenase 1 (BCMO1) promoter. Nucleotides are numbered relative to the transcriptional start site (+1) [34]. Potential consensus sequences for transcription factor binding sites are underlined and labeled. The sequence was analyzed according to the TESS program and TRACSFAC transcription factor database.

B. Alignment of ~900-bp of human and mouse proximal BCMO1 genomic sequence by the ClustalW (1.82) program [55]. The numbering is relative to the transcription initiation site (+1). The sequences in bold and labeled indicate putative DNA regulatory elements common to the two promoters.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2199-7-7-S1.pdf>]

**Additional file 2**

MEF2 and PPAR transcription factors bind to and transactivate the BCMO1 promoter

**A.** Profile of RAR $\beta$ , RXR $\alpha$ , MEF2 and PPAR transcription factors expressed in TC-7 cells. Total protein was extracted from TC-7 cells and specific immunoreactive proteins were determined by western blotting using the indicated antibodies and methods described in "Methods".

**B.** The oligonucleotides, each matching the human BCMO1 promoter wild type or mutated MEF2 site or PPAR site. Mutated base pairs are underlined.

**C.** MEF2 proteins binding to sequence in the BCMO1 promoter described in Panel B, was characterized by EMSA. Oligomers were end-labeled with [ $\gamma$ -<sup>32</sup>P]-ATP and incubated with nuclear extracts from TC-7 cells (see "Methods"). Addition of 100-fold molar excess of unlabeled competitor oligomers or mutated probes is indicated above each lane (left panel). Supershift analyses (right panel) were performed by preincubating nuclear extracts from TC-7 cells with anti-MEF2A, MEF2C and MEF2D antibodies. Arrowheads indicate specific complexes and the SS indicates supershifted bands.

**D.** PPAR proteins binding to sequence in the BCMO1 promoter described in Panel B, was characterized by EMSA. Oligomers were end-labeled with [ $\gamma$ -<sup>32</sup>P]-ATP and incubated with nuclear extracts from TC-7 cells (see "Methods"). Addition of 100-fold molar excess of unlabeled competitor oligomers or mutated probes is indicated above each lane (left panel). Supershift analyses (right panel) were performed by preincubating nuclear extracts from TC-7 cells with anti-PPAR $\alpha$ , PPAR $\gamma$ , PPAR $\delta$ , RXR $\alpha$  and RAR $\beta$  antibodies. Arrowheads indicate specific complexes and SS indicates supershifted bands.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2199-7-7-S2.pdf>]

**Additional file 3**

MEF2C cooperates with PPAR $\gamma$ /RXR $\alpha$  to activate the BCMO1 promoter in TC-7 Cells

**A.** Effects of the empty expression vector (pcDNA3), MEF2C and the dominant negative MEF2A-131 (DnMEF2) on BCMO1 promoter activity. TC-7 cells were transiently transfected as indicated. Luciferase and  $\beta$ -Gal activities were measured 24 hours after transfection and relative fold of luciferase activity (compared to pGL3-Basic) was determined after adjustment for  $\beta$ -Gal activity. Results are presented as means  $\pm$  S.D. of three independent experiments each performed in triplicate. \*, p < 0.05, \*\*, p < 0.001. **B.** MEF2C and PPAR $\gamma$ /RXR $\alpha$  activate the BCMO1 gene promoter. TC-7 cells were transiently transfected with the pGL3-BCO218 reporter vector in the absence or presence of MEF2C, PPAR $\gamma$ , RXR $\alpha$  or empty expression vector, pcDNA3, as indicated. Luciferase and  $\beta$ -Gal activity were measured 24 hours after transfection and relative fold luciferase activity was determined after adjusting for  $\beta$ -Gal activity. Results are presented as means  $\pm$  S.D. of three independent experiments each performed in triplicate. \*, p < 0.05, \*\*, p < 0.001. **C.** Effects of PPAR $\gamma$ /RXR $\alpha$  on BCMO1 promoter activity. TC-7 cells were transiently transfected with the native (pGL3-BCO147) or PPAR-mutated (pGL3-BCO147-mtPPAR) BCMO1 minimal promoter constructs. Co-transfections were performed with the empty mammalian expression vector pcDNA3 or with vector containing PPAR $\gamma$  and RXR $\alpha$ , as indicated. Luciferase and  $\beta$ -Gal activity were measured 24 hours after transfection and relative fold luciferase activity was determined after adjusting for  $\beta$ -Gal activity. Results are presented as means  $\pm$  S.D. of three independent experiments each performed in triplicate. \*\*, p < 0.001. **D.** Mutation of MEF2 and PPAR DNA binding sites prevents BCMO1 promoter activation by MEF2C and PPAR $\gamma$ /RXR $\alpha$ . TC-7 cells were transiently transfected with 0.3  $\mu$ g/well of wild-type (pGL3-BCO218) or mutant (pGL3-BCO218-mtPPAR, pGL3-BCO218-mtMEF2) reporter constructs and with expression vectors for MEF2C or PPAR $\gamma$ /RXR $\alpha$  alone or in combination. Luciferase and  $\beta$ -Gal activity were measured 24 hours after transfection and relative fold of luciferase activity was determined after adjusting for  $\beta$ -Gal activity. Results are presented as means  $\pm$  S.D. of three independent experiments each performed in triplicate. All results are significantly decreased compared with wild-type reporter activity. \*, p < 0.05, \*\*, p < 0.001.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2199-7-7-S3.pdf>]

**Acknowledgements**

This work was supported by National Institutes of Health Grants R01-HD42174 and P20-RR18722 (to L.P.R.) and R01-ES007965 and R01-GM061988 (to B.Y).

**References**

1. Goodman DS: **Vitamin A and retinoids in health and disease.** *N Engl J Med* 1984, **310**:1023-1031.
2. Vermot J, Pourquie O: **Retinoic acid coordinates somitogenesis and left-right patterning in vertebrate embryos.** *Nature* 2005, **435**:215-220.
3. Zile MH: **Function of vitamin A in vertebrate embryonic development.** *J Nutr* 2001, **131**:705-708.
4. Clagett-Dame M, DeLuca H: **The role of vitamin A in mammalian reproduction and embryonic development.** *Annu Rev Nutr* 2002, **22**:347-381.
5. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY: **Retinoic acid imprints gut-homing specificity on T cells.** *Immunity* 2004, **21**:527-538.
6. Bok D: **Photoreceptor "retinoid pumps" in health and disease.** *Neuron* 1999, **23**:412-414.

7. DeLuca LM: **Retinoids and their receptors in differentiation, embryogenesis, and neoplasia.** *FASEB J* 1991, **5**:2924-2933.
8. Ross AC: **Vitamin A status: relationship to immunity and the antibody response.** *Proc Soc Exp Biol Med* 1992, **200**:303-320.
9. Moon RC, Itri LM: **In the Retinoids.** Volume 2. Edited by: Sporn MB, Roberts AB, Goodman DS. Academic Press, Orlando, FL; 1984:327-371.
10. Parker RS: **Absorption, metabolism, and transport of carotenoids.** *FASEB J* 1996, **10**:542-551.
11. Olson JA, Hayaishi O: **The enzymatic cleavage of beta-carotene into vitamin A by soluble enzymes of rat liver and intestine.** *Proc Natl Acad Sci USA* 1965, **54**:1364-1370.
12. Goodman DS, Huang HS: **Biosynthesis of vitamin A with rat intestinal enzymes.** *Science* 1965, **149**:879-880.
13. Wolf G: **The enzymatic cleavage of beta-carotene: end of a controversy.** *Nutr Rev* 2001, **59**:116-118.
14. Kiefer C, Hessel S, Lampert JM, Vogt K, Lederer MO, Breithaupt DE, von Lintig J: **Identification and characterization of a mammalian enzyme catalyzing the asymmetric oxidative cleavage of provitamin A.** *J Biol Chem* 2001, **276**:14110-14116.
15. Wang XD: **Review: absorption and metabolism of beta-carotene.** *J Am Coll Nutr* 1994, **13**:314-325.
16. Shapiro SS, Mott DJ, Machlin LJ: **Kinetic characteristics of beta-carotene uptake and depletion in rat tissue.** *J Nutr* 1984, **114**:1924-1933.
17. Blomstrand R, Werner B: **Studies on the intestinal absorption of radioactive beta-carotene and vitamin A in man. Conversion of beta-carotene into vitamin A.** *Scand J Clin Lab Invest* 1967, **19**:339-345.
18. Lemke SL, Dueker SR, Follett JR, Lin Y, Carkeet C, Buchholz BA, Vogel JS: **Absorption and retinol equivalence of beta-carotene in humans is influenced by dietary vitamin A intake.** *J Lipid Res* 2003, **44**:1591-1600.
19. Burri BJ, Clifford AJ: **Carotenoid and retinoid metabolism: insights from isotope studies.** *Arch Biochem Biophys* 2004, **430**:110-119.
20. Bachmann H, Desbarats A, Pattison P, Sedgewick M, Riss G, Wyss A, Cardinali N, Duszka C, Goralczyk R, Grolier P: **Feedback regulation of beta, beta-carotene 15,15'-monooxygenase by retinoic acid in rats and chickens.** *J Nutr* 2002, **132**:3616-3622.
21. Boulanger A, McLemore P, Copeland NG, Gilbert DJ, Jenkins NA, Yu SS, Gentleman S, Redmond TM: **Identification of beta-carotene 15, 15'-monooxygenase as a peroxisome proliferator-activated receptor target gene.** *FASEB J* 2003, **17**:1304-1306.
22. Nagao A, Olson JA: **Enzymatic formation of 9-cis, 13-cis, and all-trans retinals from isomers of beta-carotene.** *FASEB J* 1994, **8**:968-973.
23. Nagao A, During A, Hoshino C, Terao J, Olson JA: **Stoichiometric conversion of all trans-beta-carotene to retinal by pig intestinal extract.** *Arch Biochem Biophys* 1996, **328**:57-63.
24. During A, Nagao A, Hoshino C, Terao J: **Assay of beta-carotene 15, 15'-dioxygenase activity by reverse-phase high-pressure liquid chromatography.** *Anal Biochem* 1996, **241**:199-205.
25. Wingender E, Chen X, Hehl R, Karas H, Liebich I, Matys V, Meinhardt T, Pruss M, Reuterand I, Schacherer F: **TRANSFAC: an integrated system for gene expression regulation.** *Nucleic Acids Res* 2000, **28**:316-319.
26. During A, Albaugh G, Smith JC Jr: **Characterization of beta-carotene 15,15'-dioxygenase activity in TC-7 clone of human intestinal cell line CaCo-2.** *Biochem Biophys Res Commun* 1998, **249**:467-474.
27. Zhao M, New L, Kravchenko VV, Kato Y, Gram H, Di Padova F, Olson EN, Ulevitch RJ, Han J: **Regulation of the MEF2 family of transcription factors by p38.** *Mol Cell Biol* 1999, **19**:21-30.
28. Moore T: **Vitamin A and carotene. VI. The conversion of carotene to vitamin A in vivo.** *Biochem J* 1930, **24**:696-702.
29. Wyss A, Wirtz G, Woggon W, Brugger R, Wyss M, Friedlein A, Bachmann H, Hunziker W: **Cloning and expression of beta,beta-carotene 15,15'-dioxygenase.** *Biochem Biophys Res Commun* 2000, **271**:334-336.
30. Von Lintig J, Vogt K: **Filling the gap in vitamin A research. Molecular identification of an enzyme cleaving beta-carotene to retinal.** *J Biol Chem* 2000, **275**:11915-11920.
31. Wyss A, Wirth GM, Woggon WD, Brugger R, Wyss M, Friedlein A, Riss G, Bachmann H, Hunziker W: **Expression pattern and localization of beta,beta-carotene 15,15'-dioxygenase in different tissues.** *Biochem J* 2001, **354**:521-529.
32. Redmond TM, Gentleman S, Duncan T, Yu S, Wiggert B, Gantt E, Cunningham FX Jr: **Identification, expression, and substrate specificity of a mammalian beta-carotene 15,15'-dioxygenase.** *J Biol Chem* 2001, **276**:6560-6565.
33. Paik J, During A, Harrison EH, Mendelsohn CL, Lai K, Blaner WS: **Expression and characterization of a murine enzyme able to cleave beta-carotene. The formation of retinoids.** *J Biol Chem* 2001, **276**:32160-32168.
34. Yan W, Jang G-F, Haeseleer F, Esumi N, Chang J, Kerrigan M, Campochiaro M, Canpocharo P, Palczewski K, Zack DJ: **Cloning and characterization of a human beta,beta-carotene-15,15'-dioxygenase that is highly expressed in the retinal pigment epithelium.** *Genomics* 2001, **72**:193-202.
35. Lindqvist A, Andersson S: **Biochemical properties of purified recombinant human beta-carotene 15,15'-monooxygenase.** *J Biol Chem* 2002, **277**:23942-23948.
36. Leuenberger MG, Engeloch-Jarret C, Woggon W-D: **The Reaction Mechanism of the Enzyme-Catalyzed Central Cleavage of beta-Carotene to Retinal.** *Angew Chem Int Ed* 2001, **40**:2614-2617.
37. Napoli JL, Race KR: **Biogenesis of retinoic acid from beta-carotene. Differences between the metabolism of beta-carotene and retinal.** *J Biol Chem* 1988, **263**:17372-17377.
38. Mahraoui L, Rodolosse A, Barbat A, Dussaux E, Zweibaum A, Rousset M, Brot-Laroche E: **Presence and differential expression of SGLT1, GLUT1, GLUT2, GLUT3 and GLUT5 hexose-transporter mRNAs in CaCo-2 cell clones in relation to cell growth and glucose consumption.** *Biochem J* 1994, **298**:629-633.
39. Tandy S, Williams M, Leggett A, Lopez-Jimenez M, Dedes M, Ramesh B, Srai SK, Sharp P: **Nramp2 expression is associated with pH-dependent iron uptake across the apical membrane of human intestinal CaCo-2 cells.** *J Biol Chem* 2000, **275**:1023-1029.
40. Goodman DS, Blomstrand R, Werner R, Huang HS, Shiratori T: **The intestinal absorption and metabolism of vitamin A and beta-carotene in man.** *J Clin Invest* 1966, **45**:1615-1623.
41. Wittkopp PJ, Haerum BK, Clark AG: **Evolutionary changes in cis and trans gene regulation.** *Nature* 2004, **430**:85-88.
42. Castillo-Davis CI, Hartl DL, Achaz G: **cis-Regulatory and protein evolution in orthologous and duplicate genes.** *Genome Res* 2004, **14**:1530-1536.
43. Yuh CH, Bolouri EH, Davidson EH: **Genomic cis-regulatory logic: experimental and computational analysis of a sea urchin gene.** *Science* 1998, **279**:1896-1902.
44. Berman BP, Nibu Y, Pfeiffer BD, Tomancak P, Celniker SE, Levine M, Rubin GM, Eisen MB: **Exploiting transcription factor binding site clustering to identify cis-regulatory modules involved in pattern formation in the Drosophila genome.** *Proc Natl Acad Sci USA* 2002, **99**:757-762.
45. Wasserman WW, Fickett JW: **Identification of regulatory regions which confer muscle-specific gene expression.** *J Mol Biol* 1998, **278**:167-181.
46. Bina N, Wyss P, Ren W, Szpankowski W, Thomas E, Randhawa R, Reddy S, John PM, Parea-Matos EI, Stein A, Xu H, Lazarus SA: **Exploring the characteristics of sequence elements in proximal promoters of human genes.** *Genomics* 2004, **84**:929-940.
47. Black BL, Olson EN: **Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins.** *Annu Rev Cell Dev Biol* 1998, **14**:167-96.
48. McKinsey TA, Zhang CL, Olson EN: **MEF2: a calcium-dependent regulator of cell division, differentiation and death.** *Trends Biochem Sci* 2002, **27**(1):40-7.
49. Ornaty OI, McDermott JC: **MEF2 protein expression, DNA binding specificity and complex composition, and transcriptional activity in muscle and non-muscle cells.** *J Biol Chem* 1996, **271**:24927-33.
50. Wang X, Tang X, Gong X, Albanis E, Friedman SL, Mao Z: **Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2.** *Gastroenterology* 2004, **127**:1174-88.
51. Lee Y, Nadal-Ginard B, Mahdavi V, Izumo S: **Myocyte-specific enhancer factor 2 and thyroid hormone receptor associate and synergistically activate the alpha-cardiac myosin heavy-chain gene.** *Mol Cell Biol* 1997, **17**:2745-55.

52. Baldan A, Relat J, Marrero PF, Haro D: **Functional interaction between peroxisome proliferator-activated receptors-alpha and Mef-2C on human carnitine palmitoyltransferase Ibeta (CPT1beta) gene activation.** *Nucleic Acids Res* 2004, **32**:4742-4749.
53. Chantret I, Rodolosse A, Barbat A, Dussaulx E, Brot-Laroche E, Zweibaumand A, Rousset M: **Differential expression of sucrase-isomaltase in clones isolated from early and late passages of the cell line CaCo-2: evidence for glucose-dependent negative regulation.** *J Cell Sci* 1994, **107**:213-225.
54. **Ensembl Genome Browser** [<http://www.ensembl.org/>]
55. Thompson JD, Higgins DG, Gibson TJ: **Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.** *Nucleic Acids Res* 1994, **22**:4673-4680.

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

